Nathalie S Seta

List of Publications by Year
in descending order

148 papers	5,891 citations	71102 41 h-index	95266 68 g-index
164 all docs	164 docs citations	164 times ranked	6032 citing authors

#	Article	IF	Citations
1	Influence of the environmental relative humidity on the inflammatory response of skin model after exposure to various environmental pollutants. Environmental Research, 2021, 196, 110350.	7.5	9
2	Expanding the phenotype of Xâ€linked SSR4â€“CDG: Connective tissue implications. Human Mutation, 2021, 42, 142-149.	2.5	7
3	Two Novel Homozygous Mutations in Phosphoglucomutase 3 Leading to Severe Combined Immunodeficiency, Skeletal Dysplasia, and Malformations. Journal of Clinical Immunology, 2021, 41, 958-966.	3.8	6
4	A mutation in SLC37A4 causes a dominantly inherited congenital disorder of glycosylation characterized by liver dysfunction. American Journal of Human Genetics, 2021, 108, 1040-1052.	6.2	7
5	Serum bikunin isoforms in congenital disorders of glycosylation and linkeropathies. Journal of Inherited Metabolic Disease, 2020, 43, 1349-1359.	3.6	12
6	Long term outcome of <scp>MPIâ€CDG</scp> patients on Dâ€mannose therapy. Journal of Inherited Metabolic Disease, 2020, 43, 1360-1369.	3.6	16
7	A Genome-Wide CRISPR-Cas9 Screen Identifies the Dolichol-Phosphate Mannose Synthase Complex as a Host Dependency Factor for Dengue Virus Infection. Journal of Virology, 2020, 94, .	3.4	30
8	Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. Journal of Thrombosis and Haemostasis, 2019, 17, 1798-1807.	3.8	18
9	Asthma and allergic rhinitis risk depends on house dust mite specific IgE levels in PARIS birth cohort children. World Allergy Organization Journal, 2019, 12, 100057.	3.5	30
10	An in vitro model to evaluate the impact of environmental fine particles (PM0.3-2.5) on skin damage. Toxicology Letters, 2019, 305, 94-102.	0.8	25
11	Novel variants and clinical symptoms in four new ALG3â€CDG patients, review of the literature, and identification of AAGRPâ€ALG3 as a novel ALG3 variant with alanine and glycineâ€rich Nâ€terminus. Human Mutation, 2019, 40, 938-951.	2.5	12
12	Dilated cardiomyopathy and limb-girdle muscular dystrophy-dystroglycanopathy due to novel pathogenic variants in the DPM3 gene. Neuromuscular Disorders, 2019, 29, 497-502.	0.6	7
13	International clinical guidelines for the management of phosphomannomutase 2â€congenital disorders of glycosylation: Diagnosis, treatment and follow up. Journal of Inherited Metabolic Disease, 2019, 42, 5-28.	3.6	91
14	A National French consensus on gene lists for the diagnosis of myopathies using next-generation sequencing. European Journal of Human Genetics, 2019, 27, 349-352.	2.8	27
15	Wide clinical spectrum in ALG8-CDG: clues from molecular findings suggest an explanation for a milder phenotype in the first-described patient. Pediatric Research, 2019, 85, 384-389.	2.3	8
16	Long-term follow-up in PMM2-CDG: are we ready to start treatment trials?. Genetics in Medicine, 2019, 21, 1181-1188.	2.4	36
17	Congenital disorders of glycosylation (CDG): Quo vadis?. European Journal of Medical Genetics, 2018, 61, 643-663.	1.3	191
18	CCDC115-CDG: A new rare and misleading inherited cause of liver disease. Molecular Genetics and Metabolism, 2018, 124, 228-235.	1.1	20

#	Article	IF	Citations
19	Serum bikunin is a biomarker of linkeropathies. Clinica Chimica Acta, 2018, 485, 178-180.	1.1	8
20	SLC10A7 mutations cause a skeletal dysplasia with amelogenesis imperfecta mediated by GAG biosynthesis defects. Nature Communications, 2018, 9, 3087.	12.8	39
21	Complementarity of electrophoretic, mass spectrometric, and gene sequencing techniques for the diagnosis and characterization of congenital disorders of glycosylation. Electrophoresis, 2018, 39, 3123-3132.	2.4	29
22	Two-dimensional electrophoresis highlights haptoglobin beta chain as an additional biomarker of congenital disorders of glycosylation. Clinica Chimica Acta, 2017, 470, 70-74.	1.1	11
23	220th ENMC workshop: Dystroglycan and the dystroglycanopathies Naarden, The Netherlands, 27â€“29 May 2016. Neuromuscular Disorders, 2017, 27, 387-395.	0.6	7
24	Clinical, laboratory and molecular findings and long-term follow-up data in 96 French patients with PMM2-CDG (phosphomannomutase 2-congenital disorder of glycosylation) and review of the literature. Journal of Medical Genetics, 2017, 54, 843-851.	3.2	88
25	Impact of Mycotoxins Secreted by Aspergillus Molds on the Inflammatory Response of Human Corneal Epithelial Cells. Toxins, 2017, 9, 197.	3.4	20
26	A case of fatal Type I congenital disorders of glycosylation (CDG I) associated with low dehydrodolichol diphosphate synthase (DHDDS) activity. Orphanet Journal of Rare Diseases, 2016, 11, 84.	2.7	50
27	ISPD produces CDP-ribitol used by FKTN and FKRP to transfer ribitol phosphate onto Î±-dystroglycan. Nature Communications, 2016, 7, 11534.	12.8	113
28	Abnormal Glycosylation Profile and High Alpha-Fetoprotein in a Patient with Twinkle Variants. JIMD Reports, 2016, 29, 109-113.	1.5	5
29	Allergic sensitisation in early childhood: Patterns and related factors in PARIS birth cohort. International Journal of Hygiene and Environmental Health, 2016, 219, 792-800.	4.3	31
30	In vitro model adapted to the study of skin ageing induced by air pollution. Toxicology Letters, 2016, 259, 60-68.	0.8	30
31	Early polysensitization is associated with allergic multimorbidity in PARIS birth cohort infants. Pediatric Allergy and Immunology, 2016, 27, 831-837.	2.6	46
32	ALG6â€CDG: a recognizable phenotype with epilepsy, proximal muscle weakness, ataxia and behavioral and limb anomalies. Journal of Inherited Metabolic Disease, 2016, 39, 713-723.	3.6	36
33	Human Reconstituted Nasal Epithelium, a promising in vitro model to assess impacts of environmental complex mixtures. Toxicology in Vitro, 2016, 32, 55-62.	2.4	4
34	Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. Journal of Neuromuscular Diseases, 2015, 2, 27-38.	2.6	32
35	MALDIâ€TOF MS applied to apoCâ€III glycoforms of patients with congenital disorders affecting Oâ€glycosylation. Comparison with twoâ€dimensional electrophoresis. Proteomics - Clinical Applications, 2015, 9, 787-793.	1.6	20
36	From splitting GLUT1 deficiency syndromes to overlapping phenotypes. European Journal of Medical Genetics, 2015, 58, 443-454.	1.3	52

#	Article	IF	Citations
37	Dystroglycanopathies: About Numerous Genes Involved in Glycosylation of One Single Glycoprotein. Journal of Neuromuscular Diseases, 2015, 2, 27-38.	2.6	19
38	29 French adult patients with PMM2-congenital disorder of glycosylation: outcome of the classical pediatric phenotype and depiction of a late-onset phenotype. Orphanet Journal of Rare Diseases, 2014, 9, 207.	2.7	52
39	Homozygous Truncating Intragenic Duplication in TUSC3 Responsible for Rare Autosomal Recessive Nonsyndromic Intellectual Disability with No Clinical or Biochemical Metabolic Markers. JIMD Reports, 2014, 20, 45-55.	1.5	12
40	Experimental elements towards induction of premature skin aging related with tobacco smoke exposure. Toxicology Letters, 2014, 229, S129.	0.8	0
41	A Cause of Permanent Ketosis: GLUT-1 Deficiency. JIMD Reports, 2014, 18, 79-83.	1.5	7
42	A model of human nasal epithelial cells adapted for direct and repeated exposure to airborne pollutants. Toxicology Letters, 2014, 229, 144-149.	0.8	21
43	Manganese Superoxide Dismutase (SOD2) Polymorphisms, Plasma Advanced Oxidation Protein Products (AOPP) Concentration and Risk of Kidney Complications in Subjects with Type 1 Diabetes. PLoS ONE, 2014, 9, e96916.	2.5	31
44	Arsenic urinary concentrations in children living in a naturally arsenic contaminated area. Journal of Exposure Science and Environmental Epidemiology, 2013, 23, 145-150.	3.9	10
45	Catalase activity, allelic variations in the catalase gene and risk of kidney complications in patients with type 1 diabetes. Diabetologia, 2013, 56, 2733-2742.	6.3	14
46	Partial effectiveness of acetazolamide in a mild form of GLUT1 deficiency: A pediatric observation. Movement Disorders, 2013, 28, 1749-1751.	3.9	9
47	No Mutation in the SLC2A3 Gene in Cohorts of GLUT1 Deficiency Syndromeâ€“Like Patients Negative for SLC2A1 and in Patients with AHC Negative for ATP1A3. JIMD Reports, 2013, 12, 115-120.	1.5	4
48	Cobblestone lissencephaly: neuropathological subtypes and correlations with genes of dystroglycanopathies. Brain, 2012, 135, 469-482.	7.6	151
49	Inflammatory response modulation of airway epithelial cells exposed to formaldehyde. Toxicology Letters, 2012, 211, 159-163.	0.8	38
50	Identification of Mutations in TMEM5 and ISPD as a Cause of Severe Cobblestone Lissencephaly. American Journal of Human Genetics, 2012, 91, 1135-1143.	6.2	126
51	Intragenic rearrangements in LARGE and POMGNT1 genes in severe dystroglycanopathies. Neuromuscular Disorders, 2011, 21, 782-790.	0.6	13
52	Effect of formaldehyde on corneal epithelial cells in an airâ€“liquid culture model. Toxicology Letters, 2011, 205, S120.	0.8	0
53	Sequential airâ€“liquid exposure of human respiratory cells to chemical and biological pollutants. Toxicology Letters, 2011, 207, 53-59.	0.8	22
54	Expanding the Spectrum of PMM2-CDG Phenotype. JIMD Reports, 2011, 5, 123-125.	1.5	13

#	Article	IF	Citations
55	Urinary arsenic concentrations and speciation in residents living in an area with naturally contaminated soils. Science of the Total Environment, 2010, 408, 1190-1194.	8.0	43
56	Does arsenic in soil contribute to arsenic urinary concentrations in a French population living in a naturally arsenic contaminated area?. Science of the Total Environment, 2010, 408, 6011-6016.	8.0	10
57	Guanosine diphosphate-mannose:GlcNAc2-PP-dolichol mannosyltransferase deficiency (congenital) Tj ETQq1 1 0.784314 rgBT /Overlock Genetics, 2010, 47, 729-735.	3.2	39
58	Absence of Mutation in theSLC2A1Gene in a Cohort of Patients with Alternating Hemiplegia of Childhood (AHC). Neuropediatrics, 2010, 41, 267-269.	0.6	13
59	POMGnT1, POMT1, and POMT2 Mutations in Congenital Muscular Dystrophies. Methods in Enzymology, 2010, 479, 343-352.	1.0	5
60	An in vitro model to evaluate the inflammatory response after gaseous formaldehyde exposure of lung epithelial cells. Toxicology Letters, 2010, 195, 99-105.	0.8	51
61	Should PMM2-deficiency (CDG Ia) be searched in every case of unexplained hydrops fetalis?. Molecular Genetics and Metabolism, 2010, 101, 253-257.	1.1	32
62	Conotruncal heart defects in three patients with congenital disorder of glycosylation type Ia (CDG) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50	3.2	24
63	Assessment and predictor determination of indoor aldehyde levels in Paris newborn babiesâ€™ homes. Indoor Air, 2009, 19, 314-323.	4.3	58
64	POMT2 intragenic deletions and splicing abnormalities causing congenital muscular dystrophy with mental retardation. European Journal of Medical Genetics, 2009, 52, 201-206.	1.3	24
65	The clinical spectrum of phosphomannose isomerase deficiency, with an evaluation of mannose treatment for CDG-Ib. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2009, 1792, 841-843.	3.8	103
66	Four Caucasian patients with mutations in the fukutin gene and variable clinical phenotype. Neuromuscular Disorders, 2009, 19, 182-188.	0.6	36
67	An in vitro model to assess the impact on respiratory cells of air pollutants. Toxicology Letters, 2009, 189, S86.	0.8	0
68	Cardiomyopathy in the congenital disorders of glycosylation (CDG): a case of late presentation and literature review. Journal of Inherited Metabolic Disease, 2009, 32, 313-319.	3.6	32
69	Assesment of Effects of Formaldehyde Exposure on Respiratory Health: An Innovative in vitro Model. Epidemiology, 2009, 20, S116.	2.7	0
70	Two dimensional gel electrophoresis of apolipoprotein Câ€III and MALDIâ€TOF MS are complementary techniques for the study of combined defects in Nâ€•and mucin type Oâ€glycan biosynthesis. Proteomics - Clinical Applications, 2008, 2, 1670-1674.	1.6	7
71	Indoor airborne endotoxin assessment in homes of Paris newborn babies. Indoor Air, 2008, 18, 480-487.	4.3	28
72	Protein O-mannosyltransferase activities in lymphoblasts from patients with Î±-dystroglycanopathies. Neuromuscular Disorders, 2008, 18, 45-51.	0.6	33

#	Article	IF	Citations
73	Development of liver disease despite mannose treatment in two patients with CDG-Ib. Molecular Genetics and Metabolism, 2008, 93, 40-43.	1.1	44
74	Risk assessment of acute vascular events in congenital disorder of glycosylation type Ia. Molecular Genetics and Metabolism, 2008, 93, 444-449.	1.1	59
75	New POMT2 mutations causing congenital muscular dystrophy. Neurology, 2007, 69, 1254-1260.	1.1	62
76	Detection of an Alu insertion in the POMT1 gene from three French Walker Warburg syndrome families. Molecular Genetics and Metabolism, 2007, 90, 93-96.	1.1	24
77	Molecular heterogeneity in fetal forms of type II lissencephaly. Human Mutation, 2007, 28, 1020-1027.	2.5	58
78	Two-dimensional gel electrophoresis of apolipoprotein C-III and other serum glycoproteins for the combined screening of human congenital disorders ofO- andN-glycosylation. Proteomics - Clinical Applications, 2007, 1, 321-324.	1.6	15
79	A rapid mass spectrometric strategy for the characterization ofN- andO-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics, 2007, 7, 1800-1813.	2.2	47
80	Nasal inflammation induced by a common cold: comparison between controls and patients with nasal polyposis under topical steroid therapy. Acta Otorhinolaryngologica Italica, 2007, 27, 78-82.	1.5	4
81	Nasal inflammation and personal exposure to fine particles PM2.5 in asthmatic children. Journal of Allergy and Clinical Immunology, 2006, 117, 1382-1388.	2.9	83
82	PMM2 intronic branch-site mutations in CDG-Ia. Molecular Genetics and Metabolism, 2006, 87, 337-340.	1.1	12
83	Environmental and biological monitoring of exposure to organophosphorus pesticides: Application to occupationally and non-occupationally exposed adult populations. Journal of Exposure Science and Environmental Epidemiology, 2006, 16, 417-426.	3.9	34
84	Congenital disorders of glycosylation type I: a rare but new cause of hyperechoic kidneys in infants and children due to early microcystic changes. Pediatric Radiology, 2006, 36, 108-114.	2.0	28
85	Pesticide exposure of non-occupationally exposed subjects compared to some occupational exposure: A French pilot study. Science of the Total Environment, 2006, 366, 74-91.	8.0	78
86	A New Intronic Mutation in the DPM1 Gene Is Associated With a Milder Form of CDG Ie in Two French Siblings. Pediatric Research, 2006, 59, 835-839.	2.3	31
87	A new insight into PMM2 mutations in the French population. Human Mutation, 2005, 25, 504-505.	2.5	37
88	Insecticide Urinary Metabolites in Nonoccupationally Exposed Populations. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2005, 8, 485-512.	6.5	54
89	Underdiagnosis of mild congenital disorders of glycosylation type Ia. Pediatric Neurology, 2005, 32, 121-123.	2.1	28
90	Increased recurrence risk in congenital disorders of glycosylation type Ia (CDG-Ia) due to a transmission ratio distortion. Journal of Medical Genetics, 2004, 41, 877-880.	3.2	21

#	Article	IF	Citations
91	Indoor aldehydes: measurement of contamination levels and identification of their determinants in Paris dwellings. Environmental Research, 2003, 92, 245-253.	7.5	125
92	Nasal Epithelial and Inflammatory Response to Ozone Exposure: A Review of Laboratory-Based Studies Published Since 1985. Journal of Toxicology and Environmental Health - Part B: Critical Reviews, 2003, 6, 521-568.	6.5	23
93	A Deficiency in Dolichyl-P-glucose:Glc1Man9GlcNAc2-PP-dolichyl Î±3-Glucosyltransferase Defines a New Subtype of Congenital Disorders of Glycosylation. Journal of Biological Chemistry, 2003, 278, 9962-9971.	3.4	78
94	Abnormal Glycosylation of Red Cell Membrane Band 3 in the Congenital Disorder of Glycosylation Ig. Pediatric Research, 2003, 54, 224-229.	2.3	17
95	Neurological Presentation in Pediatric Patients with Congenital Disorders of Glycosylation Type Ia. Neuropediatrics, 2003, 34, 1-6.	0.6	49
96	Congenital Disorders of Glycosylation Type Ig Is Defined by a Deficiency in Dolichyl-P-mannose:Man7GlcNAc2-PP-dolichyl Mannosyltransferase. Journal of Biological Chemistry, 2002, 277, 25815-25822.	3.4	87
97	Increased Biosynthesis of Glycosphingolipids in Congenital Disorder of Glycosylation Ia (CDG-Ia) Fibroblasts. Pediatric Research, 2002, 52, 645-651.	2.3	12
98	Protein losing enteropathy-hepatic fibrosis syndrome in Saguenay-Lac St-Jean, Quebec is a congenital disorder of glycosylation type Ib. Journal of Medical Genetics, 2002, 39, 849-851.	3.2	24
99	Leukocyte Phosphomannomutase Activity in Diagnosis of Congenital Disorder of Glycosylation Ia. Clinical Chemistry, 2002, 48, 934-936.	3.2	9
100	Nasal lavage as a tool for the assessment of upper-airway inflammation in adults and children. Translational Research, 2002, 139, 173-180.	2.3	22
101	Leukocyte phosphomannomutase activity in diagnosis of congenital disorder of glycosylation Ia. Clinical Chemistry, 2002, 48, 934-6.	3.2	2
102	Dioxins in adipose tissue of non-occupationally exposed persons in France: correlation with individual food exposure. Chemosphere, 2001, 44, 1347-1352.	8.2	16
103	Congenital Disorder of Glycosylation Ia with Deficient Phosphomannomutase Activity but Normal Plasma Glycoprotein Pattern. Clinical Chemistry, 2001, 47, 132-134.	3.2	31
104	The T911C (F304S) substitution in the human ALG6 gene is a common polymorphism and not a causal mutation of CDG-Ic. Journal of Human Genetics, 2001, 46, 547-548.	2.3	15
105	Neurological presentation of a congenital disorder of glycosylation CDG-Ia: Implications for diagnosis and genetic counseling. American Journal of Medical Genetics Part A, 2001, 101, 46-49.	2.4	40
106	A broad spectrum of clinical presentations in congenital disorders of glycosylation I: a series of 26 cases. Journal of Medical Genetics, 2001, 38, 14-19.	3.2	204
107	Congenital disorder of glycosylation Ia with deficient phosphomannomutase activity but normal plasma glycoprotein pattern. Clinical Chemistry, 2001, 47, 132-4.	3.2	13
108	Mutations in PMM2 that cause congenital disorders of glycosylation, type Ia (CDG-Ia). Human Mutation, 2000, 16, 386-394.	2.5	136

#	Article	IF	Citations
109	Protein Glycosylation and Diseases: Blood and Urinary Oligosaccharides as Markers for Diagnosis and Therapeutic Monitoring. Clinical Chemistry, 2000, 46, 795-805.	3.2	218
110	Fluorimetric Measurement of Plasma Î±-l-Fucosidase Activity with a Centrifugal Analyzer: Reference Values in a Healthy French Adult Population. Clinical Chemistry, 2000, 46, 560-576.	3.2	6
111	Congenital disorders of glycosylation IIa cause growth retardation, mental retardation, and facial dysmorphism. Journal of Medical Genetics, 2000, 37, 875-877.	3.2	30
112	Identification of four novel PMM2 mutations in congenital disorders of glycosylation (CDG) Ia French patients. Journal of Medical Genetics, 2000, 37, 579-580.	3.2	24
113	Defect in N-glycosylation of proteins is tissue-dependent in Congenital Disorders of Glycosylation Ia. Glycobiology, 2000, 10, 1277-1281.	2.5	26
114	Protein glycosylation and diseases: blood and urinary oligosaccharides as markers for diagnosis and therapeutic monitoring. Clinical Chemistry, 2000, 46, 795-805.	3.2	82
115	Carbohydrate-deficient glycoprotein syndromes become congenital disorders of glycosylation: an updated nomenclature for CDG. First International Workshop on CDGS. Glycoconjugate Journal, 1999, 16, 669-671.	2.7	93
116	Characterization of the 415G>A (E139K) PMM2 mutation in carbohydrate-deficient glycoprotein syndrome type Ia disrupting a splicing enhancer resulting in exon 5 skipping. Human Mutation, 1999, 14, 543-544.	2.5	47
117	Alteration of mannose transport in fibroblasts from type I carbohydrate deficient glycoprotein syndrome patients. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 1999, 1453, 369-377.	3.8	5
118	Hyperinsulinemic hypoglycemia as a presenting sign in phosphomannose isomerase deficiency: A new manifestation of carbohydrate-deficient glycoprotein syndrome treatable with mannose. Journal of Pediatrics, 1999, 135, 379-383.	1.8	127
119	Le carbohydrate-deficient glycoprotein syndrome typeI : un nouvel Ã©clairage sur le mÃ©tabolisme du mannose.. Medecine/Sciences, 1999, 15, 1202.	0.2	1
120	Oncostatin M Is a Potent Stimulator of Î±₁-Antitrypsin Secretion in Lung Epithelial Cells: Modulation by Transforming Growth Factor-Î² and Interferon-Î³. American Journal of Respiratory Cell and Molecular Biology, 1998, 18, 511-520.	2.9	54
121	Endothelin-1 Secretion by Alveolar Macrophages in Systemic Sclerosis. American Journal of Respiratory and Critical Care Medicine, 1997, 156, 1429-1435.	5.6	35
122	Sequential study of serum glycoprotein fucosylation in acute hepatitis. Journal of Hepatology, 1997, 26, 265-271.	3.7	13
123	Diagnostic value of Western blotting in carbohydrate-deficient glycoprotein syndrome. Clinica Chimica Acta, 1996, 254, 131-140.	1.1	59
124	Comparison of fluconazole and amphotericin B for treatment of experimental Candida albicans endocarditis in rabbits. Antimicrobial Agents and Chemotherapy, 1996, 40, 263-266.	3.2	13
125	Compartmentalized IL-8 and elastase release within the human lung in unilateral pneumonia.. American Journal of Respiratory and Critical Care Medicine, 1996, 153, 336-342.	5.6	151
126	Interleukin-8 and neutrophils in systemic sclerosis with lung involvement.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 1363-1367.	5.6	34

#	Article	IF	Citations
127	Effect of the Platelet Activating Factor Antagonist BN52021 in Rabbits: Role in Gentamicin Nephrotoxicity. Toxicology and Applied Pharmacology, 1994, 128, 111-115.	2.8	5
128	Comparison of enhanced chemiluminescence and colorimetric techniques for the immuno-detection of Î±1-antitrypsin. Clinica Chimica Acta, 1994, 227, 175-184.	1.1	10
129	Secretion of Î±1â€antitrypsin by alveolar epithelial cells. FEBS Letters, 1994, 346, 171-174.	2.8	76
130	Effects of mechanical ventilation on diaphragmatic contractile properties in rats.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1539-1544.	5.6	254
131	Compartmentalized cytokine production within the human lung in unilateral pneumonia.. American Journal of Respiratory and Critical Care Medicine, 1994, 150, 710-716.	5.6	233
132	Interleukin 6 secretion by monocytes and alveolar macrophages in systemic sclerosis with lung involvement.. American Journal of Respiratory and Critical Care Medicine, 1994, 149, 1260-1265.	5.6	47
133	Effects of diltiazem on netilmicin-induced nephrotoxicity in rabbits. Antimicrobial Agents and Chemotherapy, 1993, 37, 1790-1798.	3.2	8
134	Cell Surface Carbohydrates of Rat Alveolar Type II Cells in Primary Culture. American Journal of Respiratory Cell and Molecular Biology, 1993, 8, 145-152.	2.9	4
135	IL6 and acute phase plasma proteins in peritoneal fluid of women with endometriosis. Clinica Chimica Acta, 1992, 210, 187-195.	1.1	39
136	Factors influencing the reaction of alpha 1-fetoprotein with concanavalin A and Lens culinaris agglutinin in crossed affinoimmunoelectrophoresis. Clinical Chemistry, 1992, 38, 1418-24.	3.2	1
137	Asialoglycoprotein receptor in human isolated hepatocytes from normal liver and its apparent increase in liver with histological alterations. Journal of Hepatology, 1991, 13, 305-309.	3.7	36
138	Changes in Î±1-acid glycoprotein serum concentrations and glycoforms in the developing human fetus. Clinica Chimica Acta, 1991, 203, 167-175.	1.1	21
139	Limited protection by small unilamellar liposomes against the renal tubular toxicity induced by repeated amphotericin B infusions in rats. Antimicrobial Agents and Chemotherapy, 1991, 35, 1303-1308.	3.2	24
140	Polyclonal antibody-based enzyme-linked immunosorbent assay of alpha 1-acid glycoprotein. Clinical Chemistry, 1990, 36, 666-668.	3.2	5
141	Polyclonal antibody-based enzyme-linked immunosorbent assay of alpha 1-acid glycoprotein. Clinical Chemistry, 1990, 36, 666-9.	3.2	2
142	Reduction in biliary excretion of ceftriaxone by diclofenac in rabbits. Antimicrobial Agents and Chemotherapy, 1989, 33, 1506-1510.	3.2	11
143	Microheterogeneity of the carbohydrate moiety of human alpha 1-acid glycoprotein in two benign liver diseases: Alcoholic cirrhosis and acute hepatitis. Clinica Chimica Acta, 1989, 186, 59-66.	1.1	34
144	Comparison of glycan microheterogeneities of alpha 1-acid glycoprotein between mothers and their newborns. Progress in Clinical and Biological Research, 1989, 300, 139-42.	0.2	0

#	Article	IF	Citations
145	Incorporation of amphotericin B (AMB) into liposomes alters AMB-induced acute nephrotoxicity in rabbits. Journal of Pharmacology and Experimental Therapeutics, 1989, 251, 311-6.	2.5	18
146	Tolerance of once-daily dosing of netilmicin and teicoplanin, alone or in combination, in healthy volunteers. Clinical Pharmacology and Therapeutics, 1988, 44, 458-466.	4.7	26
147	Modifications of Concanavalin A patterns of Î±1-acid glycoprotein and Î±2-HS glycoprotein in alcoholic liver disease. Clinica Chimica Acta, 1988, 176, 49-57.	1.1	34
148	Alterations in relative proportions of microheterogenous forms of human Î±1-acid glycoprotein in liver disease. Journal of Hepatology, 1986, 2, 245-252.	3.7	47